Maynard Um
-
-
-
-
-
-
-
Barclays Double Upgrades Celldex Therapeutics (CLDX) to Overweight
-
-
-
-
-
-
-
Barclays Starts Celldex Therapeutics (CLDX) at Underweight
-
-
-
-
-
-
-
Celldex Therapeutics (CLDX) PT Lowered to $42 at H.C. Wainwright
-
-
-
-
-
-
-
Cantor Fitzgerald Reiterates Overweight Rating on Celldex Therapeutics (CLDX)
-
-
-
-
-
-
-
Celldex (CLDX) Misses Q4 EPS by 2c
-
-
-
-
-
-
-
H.C. Wainwright Reiterates Buy Rating on Celldex Therapeutics (CLDX)
-
-
-
-
-
-
-
H.C. Wainwright Reiterates Buy Rating on Celldex Therapeutics (CLDX)
-
406,430 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

